Log in
E-mail
Password
Show password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

APELLIS PHARMACEUTICALS, INC.

(APLS)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector newsMarketScreener Strategies

Apellis Pharmaceuticals to Present at the 4th Annual Evercore ISI HealthCONx Conference

11/29/2021 | 07:01am EST

WALTHAM, Mass., Nov. 29, 2021 (GLOBE NEWSWIRE) -- Apellis Pharmaceuticals, Inc. (Nasdaq: APLS), a global biopharmaceutical company and leader in complement, today announced that the company will present at the 4th Annual Evercore ISI HealthCONx Conference on Thursday, December 2, 2021 at 8:00 a.m. ET. The conference will be held in a virtual meeting format.

The conference event will be available via a live webcast from the “Events and Presentations” page of the “Investors and Media” section of the company’s website. A replay of the webcast will be available for 90 days following the event.

About Apellis
Apellis Pharmaceuticals, Inc. is a global biopharmaceutical company that is committed to leveraging courageous science, creativity, and compassion to deliver life-changing therapies. Leaders in targeted C3 therapies, we aim to develop transformative therapies for a broad range of debilitating diseases that are driven by excessive activation of the complement cascade, including those within hematology, ophthalmology, nephrology, and neurology. For more information, please visit www.apellis.com.

Investor Contact:
Meredith Kaya
meredith.kaya@apellis.com
617.599.8178


Primary Logo


ę GlobeNewswire 2021
All news about APELLIS PHARMACEUTICALS, INC.
01/25Wedbush Lifts Apellis Pharmaceuticals' Price Target to $34 From $28, Citing Empaveli La..
MT
01/20Apellis Pharmaceuticals Unveils Plans for $300 Million Offering -- Shares Drop in After..
MT
01/20APELLIS PHARMACEUTICALS, INC. : Entry into a Material Definitive Agreement, Termination of..
AQ
01/11Raymond James Adjust Apellis Pharmaceuticals' Price Target to $112 from $116, Keeps Str..
MT
01/10Pfizer CEO says Omicron-targeted vaccine is most likely outcome
RE
01/10APELLIS PHARMACEUTICALS : Excerpt from corporate presentation dated January 2022 - Form 8-..
PU
01/10Pfizer CEO says Omicron-targeted vaccine is most likely outcome
RE
01/06Apellis Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4..
AQ
01/03Apellis Pharmaceuticals to Present at the 40th Annual J.P. Morgan Healthcare Conference
GL
2021INSIDER SELL : Apellis Pharmaceuticals
MT
More news
Analyst Recommendations on APELLIS PHARMACEUTICALS, INC.
More recommendations
Financials (USD)
Sales 2021 15,0 M - -
Net income 2021 -724 M - -
Net cash 2021 185 M - -
P/E ratio 2021 -4,46x
Yield 2021 -
Capitalization 3 757 M 3 757 M -
EV / Sales 2021 237x
EV / Sales 2022 29,2x
Nbr of Employees 486
Free-Float 82,2%
Chart APELLIS PHARMACEUTICALS, INC.
Duration : Period :
Apellis Pharmaceuticals, Inc. Technical Analysis Chart | APLS | US03753U1060 | MarketScreener
Technical analysis trends APELLIS PHARMACEUTICALS, INC.
Short TermMid-TermLong Term
TrendsBearishNeutralNeutral
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 17
Last Close Price 38,59 $
Average target price 70,50 $
Spread / Average Target 82,7%
EPS Revisions
Managers and Directors
Cedric Francois President, Chief Executive Officer & Director
Timothy Eugene Sullivan Chief Financial Officer & Treasurer
Lok Chung Chan Chairman
Pascal Deschatelets Chief Scientific Officer
Federico Grossi Chief Medical Officer
Sector and Competitors
1st jan.Capi. (M$)
APELLIS PHARMACEUTICALS, INC.-21.28%3 624
CSL LIMITED-14.20%84 148
WUXI BIOLOGICS (CAYMAN) INC.-19.72%41 757
ALEXION PHARMACEUTICALS, INC.0.00%40 336
SAMSUNG BIOLOGICS CO.,LTD.-18.16%39 159
BIOGEN INC.-8.74%32 161